Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9345724 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Jul, 2030
(6 years from now) | |
US9585912 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Jul, 2030
(6 years from now) | |
US8496973 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Mar, 2031
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10479686 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Jul, 2030
(6 years from now) |
Sodium Thiosulfate is owned by Hope Pharms.
Sodium Thiosulfate contains Sodium Thiosulfate.
Sodium Thiosulfate has a total of 4 drug patents out of which 0 drug patents have expired.
Sodium Thiosulfate was authorised for market use on 14 February, 2012.
Sodium Thiosulfate is available in solution;intravenous dosage forms.
Sodium Thiosulfate can be used as sodium thiosulfate injection is administered by intravenous injection, treatment of acute cyanide poisoning that is judged to be life threatening, sodium thiosulfate injection is indicated for sequential use with sodium nitrite for the treatment of acute cyanide poisoning.
The generics of Sodium Thiosulfate are possible to be released after 29 March, 2031.
Drugs and Companies using SODIUM THIOSULFATE ingredient
Market Authorisation Date: 14 February, 2012
Treatment: Sodium thiosulfate injection is administered by intravenous injection; Sodium thiosulfate injection is indicated for sequential use with sodium nitrite for the treatment of acute cyanide poisoning; Tr...
Dosage: SOLUTION;INTRAVENOUS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic